Clinical Trials Logo

Cluster Headache, Episodic clinical trials

View clinical trials related to Cluster Headache, Episodic.

Filter by:
  • None
  • Page 1

NCT ID: NCT05084469 Not yet recruiting - Clinical trials for Cluster Headache, Episodic

Exploration of Cluster Headache in a PET-MRI Study

F13640-AVF
Start date: November 1, 2021
Phase:
Study type: Observational

Observational study in PET-MRI using the 5-HT1A agonist PET radiotracer [18F]F13640.

NCT ID: NCT04688775 Completed - Clinical trials for Cluster Headache, Episodic

Eptinezumab in Participants With Episodic Cluster Headache

ALLEVIATE
Start date: December 23, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)

NCT ID: NCT04014634 Completed - Clinical trials for Cluster Headache, Episodic

GON-injection for a Sooner and Better Treatment of Cluster Headache

CHIANTI
Start date: August 1, 2019
Phase: Phase 4
Study type: Interventional

Cluster headache is a very severe primary headache disorder. In episodic cluster headache, attacks occur in 'bouts' (clusters) lasting weeks to months. Management of cluster headache entails a combination of attack and prophylactic treatment. Current first choice prophylactic treatment (verapamil) has considerable side effects which can be serious and include possibly fatal cardiac arrhythmias; and it can take weeks to titrate to an effective dose. Evidence has emerged that local steroid injection of the greater occipital nerve (GON) may be effective in cluster headache, but this method has not been investigated as a first line prophylactic treatment in a large, well-documented group of episodic cluster headache patients who are still free of prophylactic medication and just entered a new cluster headache episode. As such, GON-injection has not yet found its way into current treatment protocols. The investigators plan to perform this multicentre double-blind randomized controlled trial to investigate whether GON-injection is efficacious as a first-line prophylactic treatment, aiming to remove the need for high doses of daily medication - such as verapamil - with associated side effects.